Inclusion Criteria:

          -  Karnofsky performance status > 70%

          -  Expected survival of at least 3 years

          -  Informed consent signed by the subject

          -  Prostate-specific antigen (PSA) blood test within 60 days prior to registration

          -  Prostate biopsy with Gleason score and TNM staging within one year prior to
             registration

          -  No evidence of metastasis on computed tomography (CT) or magnetic resonance imaging
             (MRI) of the pelvis within 120 days prior to registration.

          -  No evidence of metastasis on bone scan within 120 days prior to registration

          -  Within 60 days prior to registration, hematologic minimal values: absolute neutrophil
             count > 1,500/mm^3

          -  Within 60 days prior to registration, hematologic minimal values: hemoglobin > 8.0
             g/dl

          -  Within 60 days prior to registration, hematologic minimal values: platelet count >
             100,000/mm^3

          -  Men of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months after completion of
             treatment

          -  Histologically proven persistent or recurrent adenocarcinoma of the prostate following
             prior external beam radiation therapy or brachytherapy

          -  Prior Androgen Deprivation or chemotherapy is allowed if discontinued at least 30 days
             prior to enrollment

          -  Concurrent disease - patients under treatment for concurrent medical conditions will
             be eligible for protocol treatment if, in the opinion of the physician responsible for
             hyperthermia treatment that the concurrent medical condition will neither interfere
             with the process of the treatment or patient assessments nor add significantly to the
             risks or complications of the treatment

        Exclusion Criteria:

          -  History of urological surgery or procedures predisposing to genitourinary (GU)
             complications after radiation, i.e., anastomoses, stricture repair, transurethral
             resection, etc. (will be determined by radiation oncologist)

          -  Prior thermal ablative therapy for prostate cancer (e.g. high-intensity focused
             ultrasound [HIFU] or cryoablation)

          -  Documented distant metastatic disease

          -  Patient with other co-morbidities that in the opinion of the treating physician would
             be a contra-indication to protocol participation (e.g. inflammatory bowel disease)

          -  Mental incompetence or criminal incarceration